Market
What will be the outcome of the Stryker-Inari Medical acquisition by March 31, 2025?
3
Resolution / Starting Odds
Completed • 25%
Delayed • 25%
Cancelled • 25%
Modified Terms • 25%
Official announcements from Stryker or Inari Medical, or SEC filings
Story
Stryker to Acquire Inari Medical for $4.9 Billion at $80 Per Share, Targeting VTE Treatments
Jan 6, 2025, 08:22 PM
Stryker Corp. has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, valuing the deal at approximately $4.9 billion. The acquisition aims to expand Stryker's portfolio into the high-growth peripheral vascular segment, particularly targeting venous thromboembolism (VTE) treatments. Inari's innovative product offerings, which include mechanical thrombectomy solutions for conditions like deep vein thrombosis and pulmonary embolism, are seen as complementary to Stryker's existing Neurovascular business. The transaction is expected to close by the end of the first quarter of 2025, pending customary closing conditions including regulatory approvals.
View original story
Similar markets
No • 50%
Yes • 50%
Less than 5% • 25%
More than 15% • 25%
10-15% • 25%
5-10% • 25%
Decrease • 25%
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Other outcome • 25%
Acquisition completed • 25%
Offer rejected • 25%
Offer revised • 25%
Acquisition completed at a different price • 25%
Acquisition rejected • 25%
Acquisition completed at proposed price • 25%
Acquisition not completed • 25%
5 or more • 25%
None • 25%
1-2 • 25%
3-4 • 25%
Acquisition Abandoned • 25%
Acquisition Delayed • 25%
Other Outcomes • 25%
Acquisition Completed • 25%
Antonio Gracias acquires controlling stake • 25%
Other outcome • 25%
Helena vetoes the deal • 25%
Deal falls through for other reasons • 25%
Ongoing Negotiations • 25%
Talks Abandoned • 25%
Completed Sale • 25%
Other Outcome • 25%
No official outcome by end of 2025 • 25%
Acquisition completed • 25%
Acquisition abandoned • 25%
Acquisition delayed • 25%